← Back to home

TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY, HEART FAILURE WITH PRESERVED EJECTION FRACTION

Clinical trials for TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY, HEART FAILURE WITH PRESERVED EJECTION FRACTION explained in plain language.

Never miss a new study

Get alerted when new TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY, HEART FAILURE WITH PRESERVED EJECTION FRACTION trials appear

Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY, HEART FAILURE WITH PRESERVED EJECTION FRACTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Major heart study seeks hidden cause of heart failure in russia

Knowledge-focused Terminated

This study aims to find out how common a specific heart muscle disease (transthyretin amyloidosis cardiomyopathy, or ATTR-CM) is among Russian patients with a certain type of heart failure. Researchers will look back at medical records and also follow some patients forward in tim…

Matched conditions: TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY, HEART FAILURE WITH PRESERVED EJECTION FRACTION

Sponsor: AstraZeneca • Aim: Knowledge-focused

Last updated Apr 01, 2026 14:43 UTC

TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY, HEART FAILURE WITH PRESERVED EJECTION FRACTION

Get alerted when new TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY, HEART FAILURE WITH PRESERVED EJECTION FRACTION trials appear

Major heart study seeks hidden cause of heart failure in russia